Alliance Pharma plc (LON:APH) has launched the UK’s only prescription treatment for vomiting and nausea during pregnancy.
Sold under the brand name Xonvea, Diclectin was licensed from Duchesnay of Canada in 2015 and has been prescribed to 33mln women over 40 years. Marketing approval from the Medicines and Healthcare products Regulatory Agency took longer than anticipated but was granted over the summer.
Nausea and vomiting are the most common medical condition during pregnancy and affects around 40% of women.
Professor Catherine Nelson-Piercy, a consultant obstetric physician, welcomed the launch of Xonvea, saying: “This delayed release formulation of doxylamine and pyridoxine has been used in millions of pregnant women worldwide.”
“Primary and secondary care doctors caring for pregnant women in the UK are now able to prescribe Xonvea, affording women in the UK a licensed option when it comes to managing this often debilitating condition.”
Alliance chief executive Peter Butterfield called the drug launch a “significant milestone” for pregnant women and the company.
“There is no other licensed treatment for nausea and vomiting of pregnancy in the UK so this is excellent news for patients and clinicians as it fulfils a significant unmet medical need," he added.